Delving into the Latest Updates on FY101 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

FY101

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hyperlipidemias

Inactive Indication-

Originator Organization

Beijing Winsunny Pharmaceutical Co., Ltd.

Active Organization

Beijing Winsunny Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的（1）评价FY101注射液单次给药在中国参与者中的安全性和耐受性。次要目的（1）评价FY101注射液单次给药在中国参与者中的药代动力学特征；（2）评价FY101注射液单次给药在中国参与者中的药效动力学特征；（3）评价FY101注射液单次给药在中国参与者中的免疫原性。

[Translation]

Primary objectives (1) To evaluate the safety and tolerability of a single dose of FY101 injection in Chinese participants. Secondary objectives (1) To evaluate the pharmacokinetic characteristics of a single dose of FY101 injection in Chinese participants; (2) To evaluate the pharmacodynamic characteristics of a single dose of FY101 injection in Chinese participants; (3) To evaluate the immunogenicity of a single dose of FY101 injection in Chinese participants.

Start Date12 May 2025

Sponsor / Collaborator

Beijing Winsunny Pharmaceutical Co., Ltd.

100 Clinical Results associated with FY101

Login to view more data

100 Translational Medicine associated with FY101

Login to view more data

100 Patents (Medical) associated with FY101

Login to view more data

100 Deals associated with FY101

Login to view more data